Sophia Genetics SA (SOPH) PT Lowered to $5 at BTIG

BTIG analyst Mark Massaro lowered the price target on Sophia Genetics SA (NASDAQ: SOPH) to $5.00 (from $6.00) while maintaining a Buy rating.

The analyst commented: "Sophia turned in a relatively challenging 2024 as they drove 4% revenue growth while growing their volumes by 11%, which implies a 6-7% decline in revenue per analysis, which declined in part due to headwinds with biopharma customers. SOPH guided for a return to double-digit revenue growth in 2025 as the company is confident in its ability to turn on customers new to SOPH's DDM platform, particularly for the newer MSK-Access liquid biopsy application. We acknowledge we were surprised to see revenue/application decline in 2024, and our Buy thesis assumes the company can turn on new customers of higher-priced applications. Management acknowledged to us that DDM "go live" implementation timing is a key lever to the growth story in 2025 and 2026. SOPH shares trade at 1.5x our lowered 2026 rev estimate of $86M (+18% Y/Y), below the small cap peer group which trades at ~2.0x. We reiterate our Buy rating and trim our PT from $6 to $5 on SOPH."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Berkshire adds significantly to Alphabet position, starts small position in DR Horton
• Air T reports revenue jump but widens operating loss in Q1 fiscal 2027